Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2023, and provides a corporate update.
Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update Read More »
The first quarter of the year saw continued strong growth, record gross margin and the launching of our first IVDR-approved product.
Devyser Diagnostics AB publishes quarterly report for the period January to March 2023 Read More »
Theranexus and the Beyond Batten Disease Foundation, have announced receipt of approval from the Food and Drug Administration for the design and primary and secondary endpoints of the pivotal Phase III trial for Batten disease CLN3, at a meeting with the Division of Rare Diseases and Medical Genetics held in mid-April.
Spago Nanomedical Towards clinic with Tumorad®
Spago Nanomedical Interim Report January-March 2023 Read More »
Biophytis SA announced that it has filed for a pre-submission meeting request with the European Medicine Agency to discuss filing for conditional Marketing Authorisation in Europe for Sarconeos in the treatment of severe form of COVID-19.
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities General Regulation, Innate Pharma SA releases its total number of shares outstanding as well as its voting rights as at May 1, 2023.
Number of shares and voting rights of Innate Pharma as of May 1, 2023 Read More »
Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041.
Ochre Bio, an innovator in chronic liver disease medicine development, has announced its participation in upcoming investor and industry conferences, sharing expert perspectives and insights across liver disease and RNA therapeutics, building and scaling startups, and the future of medicine.
Ochre Bio to Participate in Upcoming Global Industry Conferences – May 09, 2023 Read More »
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company’s supplemental Biologics License Application for Vabysmo® for the treatment of macular edema following retinal vein occlusion.
Una enfermedad inflamatoria crónica que se asocia con una morbilidad significativa más allá de las manifestaciones cutáneas.
Su manejo en atención primaria | La psoriasis y sus manifestaciones extracutáneas Read More »
